Short description
G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.
Description
G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It is also advancing rintodestrant, a potential oral selective estrogen receptor degrader, or serd, for the treatment of er+ breast cancer. It is committed to improving the lives of those impacted by cancer. It is also executing a tumor-agnostic development program, with late-stage clinical trials ongoing in multiple tumor types.
Last funding
Cannot Access
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Durham, North Carolina, United States, North America
Founded on
January 1, 2008
Exited on
May 16, 2017
Went public on
May 16, 2017
Stock symbol
GTHX
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noway Youcantaccess, Uh Ohhhh, Noway Youcantaccess, Noaccess, Blurry Noaccess, Cannot Access, Absolutely Noaccess, Noaccessforu, Nopepepe, Blurry Noaccess, Uh Ohhhh, Blurry Noaccess, Nopepepe, No Way, Uh Ohhhh
Sign in for full access
Founders
Kwok-Kin Wong, Norman Sharpless